$1.46
0.000.00%
At close: -
$1.47
0.010.68%
After Hours: 5:54 PM EDT
Comments
Loading...
Ironwood Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:IRWD | Benzinga
Ironwood Pharmaceuticals Inc has a consensus price target of $13.57 based on the ratings of 7 analysts. The high is $22 issued by JMP Securities on September 28, 2023. The low is $5 issued by Leerink Partners on September 9, 2024. The 3 most-recent analyst ratings were released by JMP Securities, Craig-Hallum, and Leerink Partners on January 30, 2025, January 22, 2025, and September 9, 2024, respectively. With an average price target of $9 between JMP Securities, Craig-Hallum, and Leerink Partners, there's an implied 512.24% upside for Ironwood Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
JMP Securities
Craig-Hallum
Leerink Partners
Wells Fargo
Piper Sandler
1calculated from analyst ratings
Analyst Ratings for Ironwood Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 01/30/2025 | Buy Now | 852.38% | JMP Securities | Roy Buchanan36% | $23 → $14 | Maintains | Market Outperform | Get Alert |
| 01/22/2025 | Buy Now | 444.22% | Craig-Hallum | Chase Knickerbocker50% | $10 → $8 | Maintains | Buy | Get Alert |
| 09/09/2024 | Buy Now | 240.14% | Leerink Partners | Faisal Khurshid29% | → $5 | Initiates | → Market Perform | Get Alert |
| 08/09/2024 | Buy Now | 716.33% | Wells Fargo | Mohit Bansal72% | $14 → $12 | Maintains | Overweight | Get Alert |
| 08/09/2024 | Buy Now | 580.27% | Craig-Hallum | Chase Knickerbocker50% | $14 → $10 | Maintains | Buy | Get Alert |
| 05/10/2024 | Buy Now | 852.38% | Craig-Hallum | Chase Knickerbocker50% | $18 → $14 | Maintains | Buy | Get Alert |
| 03/01/2024 | Buy Now | 852.38% | Wells Fargo | Mohit Bansal72% | $20 → $14 | Maintains | Overweight | Get Alert |
| 02/16/2024 | Buy Now | 1328.57% | Piper Sandler | David Amsellem69% | $20 → $21 | Maintains | Overweight | Get Alert |
| 01/17/2024 | Buy Now | 1328.57% | Craig-Hallum | Chase Knickerbocker50% | → $21 | Initiates | → Buy | Get Alert |
| 12/14/2023 | Buy Now | 1260.54% | Wells Fargo | Mohit Bansal72% | → $20 | Initiates | → Overweight | Get Alert |
| 09/28/2023 | Buy Now | 1396.6% | JMP Securities | Jason Butler56% | → $22 | Initiates | → Market Outperform | Get Alert |
| 05/23/2023 | Buy Now | 1192.52% | Piper Sandler | David Amsellem69% | $16 → $19 | Maintains | Overweight | Get Alert |
| 08/16/2022 | Buy Now | 784.35% | Wells Fargo | Jacob Hughes52% | $12 → $13 | Maintains | Equal-Weight | Get Alert |
| 04/22/2022 | Buy Now | 988.44% | Piper Sandler | David Amsellem69% | → $16 | Initiates | → Overweight | Get Alert |
FAQ
What is the target price for Ironwood Pharmaceuticals (IRWD) stock?
The latest price target for Ironwood Pharmaceuticals (NASDAQ:IRWD) was reported by JMP Securities on January 30, 2025. The analyst firm set a price target for $14.00 expecting IRWD to rise to within 12 months (a possible 852.38% upside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Ironwood Pharmaceuticals (IRWD)?
The latest analyst rating for Ironwood Pharmaceuticals (NASDAQ:IRWD) was provided by JMP Securities, and Ironwood Pharmaceuticals maintained their market outperform rating.
When was the last upgrade for Ironwood Pharmaceuticals (IRWD)?
There is no last upgrade for Ironwood Pharmaceuticals
When was the last downgrade for Ironwood Pharmaceuticals (IRWD)?
There is no last downgrade for Ironwood Pharmaceuticals.
When is the next analyst rating going to be posted or updated for Ironwood Pharmaceuticals (IRWD)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ironwood Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ironwood Pharmaceuticals was filed on January 30, 2025 so you should expect the next rating to be made available sometime around January 30, 2026.
Is the Analyst Rating Ironwood Pharmaceuticals (IRWD) correct?
While ratings are subjective and will change, the latest Ironwood Pharmaceuticals (IRWD) rating was a maintained with a price target of $23.00 to $14.00. The current price Ironwood Pharmaceuticals (IRWD) is trading at is $1.47, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.